Figure 1

Mean change in AM instantaneous symptom scores for desloratadine 2.5-, 5-, 7.5-, 10-, and 20-mg tablets compared with placebo for days 2–15. Mean changes from baseline are least-square means based on ANOVA model with treatment and center effects. TSS = total symptom score is nasal + nonnasal scores. (* P < .01 versus placebo.)